Mittelman Wealth Management Sells 8,797 Shares of Hologic, Inc. $HOLX

by · The Cerbat Gem

Mittelman Wealth Management reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 44.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,131 shares of the medical equipment provider’s stock after selling 8,797 shares during the period. Hologic comprises 0.6% of Mittelman Wealth Management’s portfolio, making the stock its 18th largest holding. Mittelman Wealth Management’s holdings in Hologic were worth $725,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Allworth Financial LP lifted its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Hologic in the 1st quarter worth approximately $1,038,000. Massachusetts Financial Services Co. MA increased its position in Hologic by 11.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 49,209 shares of the medical equipment provider’s stock worth $3,040,000 after purchasing an additional 4,918 shares during the last quarter. Wealthfront Advisers LLC raised its position in shares of Hologic by 300.7% during the 1st quarter. Wealthfront Advisers LLC now owns 45,083 shares of the medical equipment provider’s stock valued at $2,785,000 after buying an additional 33,833 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 722 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $74.26 on Friday. The firm’s 50 day simple moving average is $69.62 and its 200-day simple moving average is $65.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a one year low of $51.90 and a one year high of $80.31. The firm has a market cap of $16.52 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.01 earnings per share. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. BTIG Research reiterated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average target price of $79.77.

Check Out Our Latest Stock Report on HOLX

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).